Comparing EFA technology and EFA with high flow for COPD and bronchiectasis
Hypersecreting Patients (COPD And/or Bronchiectasic) Comparing 2 Technologies: Efa vs Efa + High Flow
This study tests whether using a new breathing device alone is better than using it with high flow for people with COPD and bronchiectasis who have trouble clearing mucus.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 95 Years |
| Sex | All |
| Sponsor | Azienda Socio Sanitaria Territoriale della Valle Olona Academic / other |
| Locations | 1 site (Somma Lombardo, Varese) |
| Trial ID | NCT06017739 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of Expiratory Flow Accelerator (EFA) technology alone versus the combination of EFA with high flow in patients suffering from chronic obstructive pulmonary disease (COPD) and bronchiectasis. Participants will undergo a 13-week trial period, which includes a crossover design where they will use one technology for six weeks, followed by a washout week, and then switch to the other technology for another six weeks. The study focuses on patients with hypersecretion issues, assessing how each intervention impacts their condition.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with COPD and bronchiectasis who experience at least two exacerbations per year.
Not a fit: Patients with cystic fibrosis, obstructive sleep apnea syndrome, or those currently experiencing an exacerbation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of respiratory symptoms in patients with COPD and bronchiectasis.
How similar studies have performed: While this approach is innovative, similar studies have not been widely reported, indicating that this may be a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * COPD diagnosed by spirometry * Bronchiectasis diagnosed by CT * 2 Exacerbation/year Exclusion Criteria: * Cystic Fibrosis * OSAS * Non Invasive Ventilation * Ineffective Cough * Exacerbation in progress * Hemodynamic Instability * severe heart failure
Where this trial is running
Somma Lombardo, Varese
- Marianna Messina — Somma Lombardo, Varese, Italy (Recruiting)
Study contacts
- Principal investigator: Marianna Messina — ASST Valle Olona
- Study coordinator: Marianna Messina
- Email: annamessina.mm@gmail.com
- Phone: +393356509059
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.